MN

Michael Nally

CEO at Generate Biomedicines and CEO/Partner at Flagship Pioneering

Boston, Massachusetts

Investor
VC
CEO

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $500,000.00

  • Max Investment:

    $15,000,000.00

  • Target Investment:

    $7,000,000.00

Skills

Sales Effectiveness
Pharmaceutical Sales
Pharmaceutical Industry
Market Access
Management
Strategy
Oncology
Biotechnology
Cross-functional Team Leadership
Product Launch
Business Strategy
Clinical Trials
Diabetes
Life Sciences
Market Analysis

Education

Lists including Michael

AM
AR
AB
AF

Based in Boston & Cambridge

668 people

AT
AS
AT
AH

All Series A Investors

14752 people

AM
AT
AS
AR

All Seed Investors

19695 people

Investments

Generate Biomedicines

Series B

Total Funding: $640M

Work Experience

GB
Generate Biomedicines, Inc.

2021

  • CEO at Generate Biomedicines

    2021

FP
Flagship Pioneering

2021

  • CEO/Partner

    2021

PI
PPG Industries

2021

  • Board Member

    2021

HH
Harbinger Health

2022

  • Member Board Of Directors

    2022

M
Merck

2016 - 2021

  • Chief Marketing Officer, Human Health

    2019 - 2021

  • President, Merck Vaccines

    2016 - 2019

M
MSD

2011 - 2016

  • Managing Director, UK and Ireland

    2014 - 2016

  • Managing Director, Sweden

    2011 - 2013

M
Merck

2003 - 2011

  • Executive Director, Strategic Initiatives and Operations

    2011 - 2011

  • Executive Director, Global Human Health Operations and Execution

    2009 - 2010

  • Director Business Development

    2008 - 2009

  • Director, Investor Relations

    2006 - 2008

  • Manager, Worldwide Human Health Financial Services

    2005 - 2006

  • Senior Financial Analyst, Corporate Financial Services

    2003 - 2005